2020davaonc.com/wp-content/uploads/2019/12/2020glob_heme...17:30 what is next for the treatment of...
TRANSCRIPT
2020
JOIN OUR CHAIRS
FRANCO CAVALLI, MDFoundation for the Institute of Oncology Research
GIOVANNI MARTINELLI, MDIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS
FOR MORE INFORMATION OR TO REGISTER, VISIT: HTTPS://CVENT.ME/WPRB9?REFID=GA-1.
FEBRUARY 13-15, 2020Lisbon, Portugal
3RD ANNUAL GLOBAL SUMMIT ON
HEMATOLOGIC MALIGNANCIES
PHILIPPE MOREAU, MDUniversity Hospital of Nantes
FOR MORE INFORMATION OR TO REGISTER, VISIT: HTTPS://CVENT.ME/WPRB9?REFID=GA-1
CHAIRS
FRANCO CAVALLI, MDPresidentFoundation for the Institute of Oncology ResearchBellinzona, Switzerland
GIOVANNI MARTINELLI, MDScientific DirectorIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCSMeldola, Italy
PHILIPPE MOREAU, MDProfessor of Clinical HematologyHead, Hematology DepartmentUniversity Hospital of NantesNantes, France
ROBIN FOÀ, MDProfessor of HematologyUniversity of Rome SapienzaRome, Italy
WOJCIECH JURCZAK, MD, PHDProfessorMaria Sklodowska-Curie InstituteKrakow, Poland
HEINZ LUDWIG, MDProfessor of Internal Medicine and Hemato-OncologyWilhelminen Cancer Research InstituteVienna, Austria
JOAQUIN MARTINEZ-LOPEZ, MD, PHDProfessorComplutense University, CNIOHospital Universitario 12 de OctubreMadrid, Spain
ROBERTO MINA, MDAssistant ProfessorDivision of HematologyUniversity of TorinoTorino, Italy
PAU MONTESINOS, MD, PHDPhysicianHospital Universitari i Politècnic La FeValencia, Spain
MARCO MONTILLO, MD, PHDMedical DirectorChronic Lymphoproliferative Disorders ProgramService of HematologyNiguarda Cancer CenterMilano, Italy
JOAN BLADÉ, MDSenior ConsultantHematology DepartmentHospital Clinic of BarcelonaBarcelona, Spain
MELETIOS DIMOPOULOS, MDProfessor and RectorDepartment of Clinical TherapeuticsNational and Kapodistrian University of AthensAthens, Greece
MONIKA DŁUGOSZ-DANECKA, MD, PHDAssociate ProfessorDepartment of Clinical OncologyMaria Sklodowska-Curie Institute Oncology Center, Krakow BranchKrakow, Poland
OLIVER OTTMANN, MDProfessorHead of HematologyCardiff UniversityCardiff, UK
TADEUSZ ROBAK, MD, PHDProfessor of HematologyMedical University of LodzLodz, Poland
DAVIDE ROSSI, MD, PHDHead, Laboratory of Experimental HematologyInstitute of Oncology ResearchBellinzona, Switzerland
ALESSANDRA TEDESCHI, MDMedical Director Niguarda Cancer CenterMilan, Italy
STEVEN TREON, MD, PHD, FRCP, FACPDirector, Bing Center for Waldenstrom’s MacroglobulinemiaProfessor, Harvard Medical SchoolDana-Farber Cancer InstituteBoston, Massachusetts, USA
PIER LUIGI ZINZANI, MD, PHDProfessor of HematologyInstitute of Hematology L. e A. SeràgnoliUniversity of BolognaBologna, Italy
3RD ANNUAL GLOBAL SUMMIT ON
HEMATOLOGIC MALIGNANCIESFEBRUARY 13-15, 2020 Lisbon, Portugal
FOR MORE INFORMATION OR TO REGISTER, VISIT: HTTPS://CVENT.ME/WPRB9?REFID=GA-1
Thursday, 13 February 17:00 Welcome and Introductions
17:15 Trends in CLL Treatment in 2020 in the EU
17:30 What is Next for the Treatment of Multiple Myeloma
17:45 Future of FLT3 Treatment in AML
18:00 Resistance to BCL2 Inhibitors in B-cell Malignancies
18:15 Uncovering New Targets for the Treatment of Multiple Myeloma
18:30 PANEL DISCUSSION AND CASE STUDIES
19:15 ADJOURN TO DINNER
Friday, 14 February 9:00 Associating Biological Characteristics and Clinical Outcomes
in CLL
9:15 Role of Single-agent Ibrutinib in CLL in 2020
9:30 Current Update on Resistance to BTK in CLL
9:45 Chemo-free Regimen Combinations in CLL
10:00 How Many BTK Inhibitors Do We Need in CLL?
10:15 Venetoclax 2020: When to Use Single Agent or Combination Therapy?
10:30 Future Role of Ibrutinib Combinations in CLL
10:45 Is There a Role for Front-line Chemoimmunotherapy in CLL?
11:00 PANEL DISCUSSION AND CASE STUDIES
11:30 BREAK
Lymphoma11:45 Improving on R-CHOP in DLBCL in 2020-2025
12:00 Current and Future Treatment Landscape in First-line and Refractory MCL
12:20 Modern MoAb: Can Monoclonal Antibodies Be Approved in Lymphoma?
12:35 Emerging Agent Showcase
12:45 PANEL DISCUSSION AND CASE STUDIES
14:00 LUNCH
Debating Technology: Utilizing Current CAR-T Therapy vs. Optimizing Future CARs15:30 Finding a Role for Current CAR-T Technology
15:40 Necessity of Optimizing CAR-T Technology
12:45 PANEL DISCUSSION
TENTATIVE AGENDA
Multiple Myeloma16:30 Translating Clinical Trial Results into Real-world Solutions
16:45 Update on Daratumumab: Newly Diagnosed and Relapsed Patients
17:00 Sequencing after First Relapse
17:15 Role of Autologous Stem Cell Transplant in Myeloma
17:30 Role of Carfilzomib in Upfront Treatment in Multiple Myeloma
17:45 PANEL DISCUSSION AND CASE STUDIES
Emerging Trends in Multiple Myeloma and Lymphoma18:30 Future Role of Immunological Therapy in Multiple Myeloma
18:45 New Maintenance Agents in Multiple Myeloma
18:55 Novel PI3K Inhibitors in Follicular Lymphoma
19:10 PANEL DISCUSSION AND CASE STUDIES
20:30 ADJOURN TO POSTER RECEPTION (Concludes: 21:30)
Saturday, 15 February 8:00 BREAKFAST
Acute Leukemias9:00 Advances in Acute Myeloid Leukemia Treatment in 2020
9:15 Role of IDH1/2 in Treatment Landscape of AML
9:30 Role of Single-agent FLT Inhibition
9:45 Role of FLT3 Inhibition Post-transplant
10:00 European Standardization for MRD in AML
10:15 Lessons Learned from MRD in ALL
10:30 PANEL DISCUSSION AND CASE STUDIES
11:00 BREAK
Emerging Trends in Acute and Chronic Lymphocytic Leukemia11:15 Engaging the Immune System in the Treatment of AML
11:30 Immune Checkpoint-based Approaches in Acute Leukemias
11:45 Feasibility of Time-limited Treatment with VenR in R/R CLL
12:00 PANEL DISCUSSION AND CASE STUDIES
Emerging Agent Showcases12:50 Emerging Agent Showcase
13:00 LUNCH AND MEETING CONCLUDES
O N C O L O G Y M E E T I N G I N N O VAT I O N S
Aryn [email protected]
Jenna [email protected]
Lauren [email protected]
davaonc.com